University of Leeds IVF Spinout IVFmicro Secures £3.5m in Pre-Seed Funding
In an exciting development for the fertility treatment landscape, IVFmicro, a pioneering spinout from the University of Leeds, has successfully raised £3.5 million in pre-seed funding. This significant investment, led by Northern Gritstone with additional support from the Innovate UK Investor Partnerships Programme, marks a vital step forward as the company gears up for its next phase of verification and validation in preparation for trials involving human embryos at fertility clinics.
Leadership and Vision
At the helm of IVFmicro are co-founders Helen Picton and Virginia Pensabene. Picton, a seasoned expert in reproductive biology and co-founder, reflects the company’s mission by stating, “Our goal is to make IVF more effective, more predictable, and ultimately more hopeful for those striving to start a family.” With a background in female reproductive biology, Picton understands the complexities of translating scientific research into practical solutions.
Addressing Global Fertility Challenges
Infertility affects approximately 1 in 6 couples worldwide, and despite advancements in IVF technology, success rates remain suboptimal. For women under 35, only about 25-30% of IVF cycles result in live births. These challenges stem from various factors, including limitations in the embryo culture process, where subjective selection and repetitive handling can undermine outcomes. Moreover, with a typical IVF cycle costing around £5,000 in the UK and extended NHS waiting lists hampering accessibility, the need for innovative solutions has never been more urgent.
The IVFmicro Solution
IVFmicro is introducing the first microfluidic device designed for embryo culture, which enhances the safety and efficiency of handling embryos using minimal amounts of nutrient-rich fluid. This precision-engineered technology aims to tackle the limitations of traditional IVF methods by improving both the quality and quantity of viable embryos. Studies indicate that IVFmicro’s approach can achieve a 10-15% enhancement in embryo viability, significantly increasing the chances of successful pregnancies.
The Founders’ Journey
Founded in 2018, IVFmicro stems from years of dedicated research conducted by its founders. Virginia Pensabene, a biomedical engineer with a strong focus on microfluidics, teamed up with Picton, who has successfully generated over £8 million in research funding. Their collaboration began in 2017 at the University of Leeds, where they sought to translate their academic research into tangible solutions for real-world applications.
Support and Future Directions
Recently, IVFmicro participated in the NG Studios life sciences program, a collaborative initiative designed to assist pre-seed life science startups. This program is backed by significant players such as KQ Labs and the Francis Crick Institute, providing invaluable resources and mentorship to help burgeoning companies refine their innovations.
Pensabene expressed her gratitude for the support received, stating, “Thanks to the combination of grant funding and Northern Gritstone’s support — both through investment and its innovation programs — we have been able to grow our team in Leeds and take a major step toward bringing this precision-engineered IVF solution to market.”
The Bigger Picture
IVFmicro’s technological advancements come at a crucial time when increasing numbers of couples are turning to assisted reproductive technologies in hopes of realizing their dreams of starting a family. By addressing critical shortcomings in current fertility treatments, IVFmicro stands to not only improve individual outcomes but also contribute positively to the broader fertility landscape. With continued innovation and investment, the future looks promising for couples facing infertility challenges, making IVF more accessible and effective than ever before.
